Recludix Pharma, a leader in discovery of inhibitors of challenging targets for inflammatory disease, today announced that ...

The following is a summary of “Allergic fungal rhinosinusitis linked to other hyper-IgE syndromes through defective TH17 ...

The combination of ACT001 and radiotherapy elicited responses and was considered well tolerated in a phase 2 trial of pediatric patients with newly diagnosed DIPG.

Bio-Path Holdings Inc (BPTH) reports progress in clinical trials and improved financial performance despite cash reserve ...

Expands DNAbilize® Technology Beyond Oncology into ObesityConference Call to be Held Today at 8:30 A.M. ETHOUSTON, Nov. 15, 2024 (GLOBE ...

A groundbreaking approach slows tumor growth while boosting the immune system’s defense against cancer cells. Prostate cancer ranks as the second most common cancer among men globally. Despite recent ...

Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024New CM24 biomarkers data presented during the third quarter of ...

Prostate cancer is the second most common cancer in men worldwide. Despite medical advances in recent years, this type of tumour is still responsible for one in eight male cancer deaths in Austria ...

Fintel reports that on November 18, 2024, Stephens & Co. initiated coverage of Kymera Therapeutics (NasdaqGM:KYMR) with a ...

Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotech ...

Analysts at Stephens initiated coverage on shares of Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) in a report issued ...